Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) has scheduled an investor conference call to discuss its second-quarter 2025 results on Wednesday, July 16th at 8:30 a.m. (Eastern Time). The call will be hosted by key executives including CEO Joaquin Duato, CFO Joseph J. Wolk, and VP of Investor Relations Darren Snellgrove.
Investors can access the call via webcast at www.investor.jnj.com or by telephone (U.S.: 877-869-3847, International: 201-689-8261). The earnings press release will be available at 6:45 a.m. ET on the day of the call. A replay will be accessible until July 30th. The company has also announced its third-quarter earnings call date for October 14th, 2025.
An FDA expert panel has called for new standards to ban talc use in consumer products including gum, candy, rice, and pharmaceuticals. The panel cited over 30 years of studies linking talc to ovarian cancer, which previously led Johnson & Johnson (JNJ) to discontinue its talc-based body powders. Dr. George Tidmarsh from Stanford University emphasized talc's carcinogenic nature, while Dr. Daniel Cramer's 1982 study showed an 82% increased risk of ovarian cancer in women regularly using talc-based powders. The National Institutes of Health and International Agency for Research on Cancer have recently upgraded talc's cancer risk classification from "possible" to "probable." Multiple tests, including FDA's own, have detected asbestos in cosmetic talc, further elevating cancer risks.
Johnson & Johnson (NYSE: JNJ) has announced its participation in Bernstein's 41st Annual Strategic Decisions Conference scheduled for May 28th, 2025. The company's management will engage in a Fireside Chat at 9:00 a.m. Eastern Time. Investors and interested parties can access a live audio webcast of the presentation through J&J's Investor Relations website. An archived version of the session will be made available approximately 48 hours after the webcast.